Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3897445 | 0.93 | — | — | |
| SCHEMBL5874140 | 0.81 | ALDH1A1 (0.38) | L3MBTL1ALDH1A1MAPTGAAPOLB | |
| SCHEMBL2950462 | 0.81 | ALDH1A1 (0.35) | L3MBTL1ALDH1A1MAPTGAAPOLB | |
| Water SCHEMBL9419678 | 0.79 | ALDH1A1 (0.34) | L3MBTL1ALDH1A1MAPTGAAPOLB | |
| SCHEMBL3910470 | 0.79 | ALDH1A1 (0.33) | L3MBTL1ALDH1A1MAPTGAAPOLB | |
| SCHEMBL3910467 | 0.79 | ALDH1A1 (0.33) | L3MBTL1ALDH1A1MAPTGAAPOLB | |
| SCHEMBL762068 | 0.77 | L3MBTL1 (0.35) | L3MBTL1ALDH1A1MAPTGAAPOLB | |
| SCHEMBL5874669 | 0.77 | ATM (0.43) | L3MBTL1ALDH1A1MAPTPOLB | |
| SCHEMBL5874399 | 0.77 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1MAPTPOLB | |
| SCHEMBL5875030 | 0.77 | ALDH1A1 (0.33) | L3MBTL1ALDH1A1MAPTGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015306-B2 | Labeled neurotensin derivatives | BIOSYNTHEMA, INC. (US) | 2006-03-21 | — | — | US | claimed |
| US-20050191240-A1 | Peptide analogs of neurotensin resistant to enzymatic degradation and retain high binding affinity for neurotensin receptors; metal chelating group on one end; replacing Arg8 with Gly(PipAm) ((N-amidinopiperidinyl)glycine) for example; useful for diagnostic and therapeutic purposes | ADVANCED ACCELERATOR APPLICATIONS USA, INC. | 2005-09-01 | — | — | US | claimed |
| EP-1194444-A2 | LABELED NEUROTENSIN DERIVATIVES WITH IMPROVED RESISTANCE TO ENZYMATIC DEGRADATION | BioSynthema Inc. (US) | 2002-04-10 | — | — | EP | claimed |
| WO-2000078796-A2 | LABELED NEUROTENSIN DERIVATIVES WITH IMPROVED RESISTANCE TO ENZYMATIC DEGRADATION | MALLINCKRODT INC. (US) | 2000-12-28 | — | — | WO | claimed |
| EP-3668886-A2 | TAU AGGREGATION PEPTIDE INHIBITORS | Adrx, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| CN-110072883-A | The relevant peptide of therapeutic MOTS-C | 科巴公司 | 2019-07-30 | — | — | CN | disclosed |
| CN-109715185-A | Water soluble and chemically stable glucagon peptides | 印第安纳大学研究及科技有限公司 | 2019-05-03 | — | — | CN | disclosed |
| WO-2019036725-A2 | TAU AGGREGATION PEPTIDE INHIBITORS | ADRX, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| CN-108697756-A | HER2 peptide reagents and method | 密歇根大学董事会 | 2018-10-23 | — | — | CN | disclosed |
| CN-104583233-B | Show the analog of the glucagon of GIP receptor actives | 印第安纳大学研究及科技有限公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-108383902-A | Insulin analog dimer | 印第安纳大学研究及科技有限公司 | 2018-08-10 | — | — | CN | disclosed |
| CN-104995207-B | β integrin-G protein α subunit binding interaction inhibitors | 伊利诺伊州大学理事会 | 2018-08-07 | — | — | CN | disclosed |
| WO-2006039221-A2 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-7015306-B2 | Labeled neurotensin derivatives | BIOSYNTHEMA, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050191240-A1 | Peptide analogs of neurotensin resistant to enzymatic degradation and retain high binding affinity for neurotensin receptors; metal chelating group on one end; replacing Arg8 with Gly(PipAm) ((N-amidinopiperidinyl)glycine) for example; useful for diagnostic and therapeutic purposes | ADVANCED ACCELERATOR APPLICATIONS USA, INC. | 2005-09-01 | — | — | US | disclosed |
| EP-1194444-A2 | LABELED NEUROTENSIN DERIVATIVES WITH IMPROVED RESISTANCE TO ENZYMATIC DEGRADATION | BioSynthema Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| CN-1079792-C | DP-IV-serine protease inhibitors | FERRING BV (NL) | 2002-02-27 | — | — | CN | disclosed |
| WO-2000078796-A2 | LABELED NEUROTENSIN DERIVATIVES WITH IMPROVED RESISTANCE TO ENZYMATIC DEGRADATION | MALLINCKRODT INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| CN-1158133-A | Peptide-derived radionuclide chelators | RESOLUTION PHARM INC (CA) | 1997-08-27 | — | — | CN | disclosed |
| CN-1141033-A | Enzyme inhibitors | FERRING BV (NL) | 1997-01-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050191240-A1 | Peptide analogs of neurotensin resistant to enzymatic degradation and retain high binding affinity for neurotensin receptors; metal chelating group on one end; replacing Arg8 with Gly(PipAm) ((N-amidinopiperidinyl)glycine) for example; useful for diagnostic and therapeutic purposes | ANPEP, DNPEP, NTSR1 | L3MBTL1 2802/4885ALDH1A1 4467/4885MAPT 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.